LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biopsies May Overlook Esophagus Disease

By LabMedica International staff writers
Posted on 25 Sep 2012
Print article
An existing diagnostic method may overlook an elusive digestive disorder that causes swelling in the esophagus and painful swallowing.

The location and density of eosinophils, which regulate allergy mechanisms in the immune system suggest the disease eosinophilic esophagitis, or EoE, may be under- or misdiagnosed in patients using the current method, which is to take tissue samples as biopsies with an endoscope.

Medical scientists at the University of Utah (Salt Lake City, UT, USA) showed that even a patient with known EoE would require more than 31 random tissue samples, or biopsies, from an area in the esophagus with low eosinophil density to reliably diagnose EoE. Currently, if a patient is suspected of having EoE, five to 12 biopsies are collected along the esophagus using an endoscope. If more than 15 eosinophils turn up in any one of these samples, a diagnosis of EoE is made.

To generate a map of eosinophil distribution in the esophagus the lead investigator examined each of 17 tissue sections taken at intervals every 0.32-0.51 cm along the esophagus of a known adult EoE patient. A typical adult esophagus is 25.4 cm long. Tissue was imaged with an Olympus microscope (Olympus, Center Valley, PA, USA) at ×400 magnification. The eosinophil count for each site was performed manually, one high-powered field (hpf) at a time, around the entire luminal perimeter. The number of sites containing a diagnostic level of eosinophils, either 15 eosinophils/hpf or 20 eosinophils/hpf was determined for each of the 17 circumferential sections.

A statistical simulation technique was used to determine whether randomly sampling tissue would result in a positive diagnosis of EoE based on eosinophil density. Leonard F. Pease, PhD, a senior author of the study said, "Our analysis shows that with current diagnostic conventions, you are only going to catch the patients with medium-to-high eosinophil densities, which means we may be misdiagnosing patients as much as one out of every five times. Given this data, clearly endoscopy is not sufficient for a disease this patchy."

The team is investigating technologies for labeling and detecting proteins shed by eosinophils in the esophagus, which would help detect EoE at an earlier stage. They have also filed a patent to use radiolabeled antibodies to map eosinophils throughout the entire esophagus, a new technique that would be evaluated with a clinical trial. The study was published in the September 2012 issue of the Journal of Allergy and Clinical Immunology.

Related Links:

University of Utah
Olympus


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.